Enliven Therapeutics, Inc.
(ELVN - NASDAQ)
44,90 USD
📋 Profilo Aziendale

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

|